NCT05923892View on ClinicalTrials.gov

Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

August 2, 2023

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2024

Conditions
Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Interventions
DRUG

OPS-2071

There are 3 dose groups of OPS-2071，OPS-2071 tablets, 50 mg、100mg、200mg. Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).

DRUG

placebo

Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).

Trial Locations (1)

430000

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

Sponsors
All Listed Sponsors
lead

Otsuka Beijing Research Institute

INDUSTRY

NCT05923892 - Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type | Biotech Hunter | Biotech Hunter